Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Accounts Payables (2022 - 2025)

Entrada Therapeutics has reported Accounts Payables over the past 4 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Accounts Payables at $2.3 million for Q4 2025, down 46.25% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (down 46.25% YoY), and the annual figure for FY2025 was $2.3 million, down 46.25%.
  • Accounts Payables for Q4 2025 was $2.3 million at Entrada Therapeutics, down from $3.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for TRDA hit a ceiling of $6.5 million in Q1 2023 and a floor of $752000.0 in Q3 2023.
  • Median Accounts Payables over the past 4 years was $2.5 million (2023), compared with a mean of $2.9 million.
  • Biggest five-year swings in Accounts Payables: plummeted 60.97% in 2024 and later surged 145.05% in 2025.
  • Entrada Therapeutics' Accounts Payables stood at $6.0 million in 2022, then plummeted by 45.29% to $3.3 million in 2023, then increased by 29.97% to $4.3 million in 2024, then plummeted by 46.25% to $2.3 million in 2025.
  • The last three reported values for Accounts Payables were $2.3 million (Q4 2025), $3.2 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.